Protagonist Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Protagonist Therapeutics

08/11/2022 22:58

* Protagonist Therapeutics Inc  PTGX.OQ  reported a
quarterly
adjusted loss of 64 cents​​ per share for the quarter ended in
September. The mean expectation of six analysts for the quarter
was for a loss of 87 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Protagonist Therapeutics Inc's reported EPS for the
quarter was
a loss of 64 cents​.
    * The mean earnings estimate of analysts had risen by
about 8% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Protagonist Therapeutics Inc shares had fallen by 8.1%
this
quarter and lost 77.3% so far this year.
    * The company reported a quarterly loss of $31.23 million.
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $35.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 10:58 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.87          -0.64          Beat
 Jun. 30 2022      -0.93          -0.84          Beat
 Mar. 31 2022      -0.63          -0.43          Beat
 Dec. 31 2021      -0.78          -0.77          Beat